This dual targeting strategy of UHRF1 and HDAC presents a potent therapeutic avenue for CRC.466 Elevated UHRF1 levels, paired with reduced tumor suppressor gene (TSG) expression, are inversely related to CRC progression and poorer patient survival, underscoring the importance of investigating key UHRF1 domains and their relevance in CRC prognosis and suggesting potential therapeutic routes. This evidence concerns the gene UHRF1 and colorectal carcinoma.